Cardenilimab and lenvatinib for kidney cancer before surgery
Part of Cancer, Kidney & urinary clinical trials.
This trial tests combining two drugs (cardenilimab and lenvatinib) before surgery for clear cell kidney cancer that can be removed. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have clear cell kidney cancer that can be surgically removed and has not spread to other parts of the body.
- You have not had any previous cancer treatment (like chemotherapy or immunotherapy) for this cancer.
- Your major organs (like blood cells, liver, kidneys, and heart) are working well enough, based on blood tests and a heart ultrasound.
- You are willing to use effective birth control during the study and for 8 weeks after the last dose.
- You do not have serious infections, other cancers, or conditions that affect your immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving pucotenlimab (an immunotherapy drug) with vorolanib (a targeted therapy) before surgery helps shrink clear cell kidney tumors and makes kidney-sparing surgery safer. It is for people with localized, non-metastatic disease where the tumor is difficult to remove with partial nephrectomy.
This trial tests whether giving pembrolizumab (an immune medicine) and lenvatinib (a targeted medicine) before surgery can shrink or better treat renal cell carcinoma. The goal is to improve surgical outcomes and help the body fight the cancer.
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to remove a kidney tumor. The goal is to see if this approach is safe and helps shrink tumors in patients with advanced but non-spreading kidney cancer.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
This trial tests a combination of two drugs, zanzalintinib and pembrolizumab, given before surgery for clear cell kidney cancer that has not spread too far. The goal is to see if the drugs help shrink the tumor and make surgery more effective.
Hear when a new Resectable Clear Cell Carcinoma of the Kidney trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.